Zobrazeno 1 - 10
of 492
pro vyhledávání: '"Xiaohong, Xie"'
Autor:
Yangdong Zhou, Weijia Guo, Lixin Xing, Zhun Dong, Yunsong Yang, Lei Du, Xiaohong Xie, Siyu Ye
Publikováno v:
ACS Central Science, Vol 10, Iss 11, Pp 2006-2015 (2024)
Externí odkaz:
https://doaj.org/article/025df3f3ab6d4200a2e93221904eeb2a
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-24 (2024)
Abstract Non-genetic mechanisms have recently emerged as important drivers of anticancer drug resistance. Among these, the drug tolerant persister (DTP) cell phenotype is attracting more and more attention and giving a predominant non-genetic role in
Externí odkaz:
https://doaj.org/article/e61132566636440fbc7b073074421f56
Autor:
Du Feng, Huixin Jiang, Gengjia Chen, Wenhui Guan, Lin Yi, Yue Zhu, Yijia Li, Gengda Huang, Bin He, Junlong Tang, Yujie Tang, Jiyuan Zeng, Wensheng Zhou, Jiayu Shi, Zhanhong Xie, Ming Liu, Xiaohong Xie, Xinqing Lin, Chengzhi Zhou
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for
Externí odkaz:
https://doaj.org/article/67951f36d7b8466aa37e5efb2a7912e4
Autor:
Xiaohong Xie, Chen Zeng, Fei Wang, Guihuan Qiu, Ziyao Chen, Ting Liu, Xinqing Lin, Zhanhong Xie, Yinyin Qin, Yansheng Wang, Xiaodong Ma, Ming Liu, Chengzhi Zhou
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e40092- (2024)
Background: Non-small cell lung cancer-not otherwise specified (NSCLC-NOS) is a rare subtype of NSCLC that cannot be classified specifically based on morphology and/or special staining. This study aimed to explore the clinical features, biological an
Externí odkaz:
https://doaj.org/article/7b0b1c85e28f41b39f0f4f562ade3d73
Autor:
Jiaxin Li, Bolin Pan, Qiying Huang, Chulan Zhan, Tong Lin, Yangzhi Qiu, Honglang Zhang, Xiaohong Xie, Xinqin Lin, Ming Liu, Liqiang Wang, Chengzhi Zhou
Publikováno v:
The Clinical Respiratory Journal, Vol 18, Iss 8, Pp n/a-n/a (2024)
ABSTRACT Background Young lung cancer is a rare subgroup accounting for 5% of lung cancer. The aim of this study was to compare the causes of death (COD) among lung cancer patients of different age groups and construct a nomogram to predict cancer‐
Externí odkaz:
https://doaj.org/article/c7b31f11b8ee498e9574f4d594e85ff6
Autor:
Ni Sun, Ru Li, Haiyi Deng, Qingyang Li, Jiaxi Deng, Yue Zhu, Wenwei Mo, Wenhui Guan, Minjuan Hu, Ming Liu, Xiaohong Xie, Xinqing Lin, Chengzhi Zhou
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo compare the prognostic differences between non-small cell lung cancer (NSCLC) patients with mild and severe checkpoint inhibitor-associated pneumonitis (CIP), and explore the causes of death and prognostic risk factors in NSCLC patients w
Externí odkaz:
https://doaj.org/article/a0acd3267d57404ea2ed28cc5e6e1e9e
Autor:
Yi Qin, Guoxia Yang, Dongbin Li, Danyidie Zhang, Zhihui Chen, Zhongyi Yang, Kaitai Yang, Xiaohong Xie, Yueyan Wu
Publikováno v:
Horticulturae, Vol 10, Iss 9, p 959 (2024)
Rhododendron, a globally popular ornamental flower, is nevertheless limited in our understanding of the mechanisms underlying its fragrance formation. Notably, terpenoids are the most prevalent volatile metabolite produced by plants. In this study, g
Externí odkaz:
https://doaj.org/article/35de9e1c7a5c4bf087790628d3cf663f
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Atypical Chronic Myeloid Leukemia (aCML), a myeloproliferative neoplasm with poor prognosis, was reclassified as aCML by the ICC classification, and as MDS/MPN with neutrophilia by the WHO 2022 classification. Due to the heterogeneity of its clinical
Externí odkaz:
https://doaj.org/article/070feebc8b0b4daea31834f68fcfa96e
Autor:
Guihuan Qiu, Fei Wang, Xiaohong Xie, Ting Liu, Chen Zeng, Ziyao Chen, Maolin Zhou, Haiyi Deng, Yilin Yang, Xinqing Lin, Zhanhong Xie, Gengyun Sun, Chengzhi Zhou, Ming Liu
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14881-14891 (2023)
Abstract Background The treatment of extensive stage small‐cell lung cancer (ES‐SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for the treatment of SCLC
Externí odkaz:
https://doaj.org/article/7f927dc7876b44539095cd23ecd983c6
Autor:
Xiaohong Xie, Wenhui Guan, Wenting Huang, Juhong Jiang, Haiyi Deng, Yijia Li, Huixin Jiang, Ming Liu, Chengzhi Zhou
Publikováno v:
Heliyon, Vol 10, Iss 2, Pp e24373- (2024)
A Chinese male patient with advanced lung adenocarcinoma experienced disease progression one and a half years after receiving first-line immunochemotherapy. The second biopsy was performed and tissue immunohistochemistry revealed Anaplastic lymphoma
Externí odkaz:
https://doaj.org/article/d1248b8b3b3444eea947a16f9c95d7b8